Your browser doesn't support javascript.
loading
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Feng, Guang-Wei; Wang, Zhong-Fang; He, Peng; Lan, Qin-Ying; Ni, Ling; Yang, Ya-Zheng; Wang, Chen-Fei; Cui, Ting-Ting; Huang, Li-Li; Yan, Yong-Qiang; Jiang, Zhi-Wei; Yang, Qing; Yu, Bang-Wei; Han, Xi; Chen, Jing-Jing; Yang, Shu-Yuan; Yuan, Lin; Zhou, Ling-Yun; Liu, Ge; Li, Ke; Huang, Zhen; Zhao, Jin-Cun; Hu, Zhong-Yu; Xie, Zhi-Qiang.
Afiliación
  • Feng GW; Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China.
  • Wang ZF; State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China.
  • He P; Division of Drug and Vaccine Research, Guangzhou Laboratory, Bioland, Guangzhou, GD, China.
  • Lan QY; Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Ni L; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Yang YZ; School of Medicine, Tsinghua University, Beijing, China.
  • Wang CF; School of Medicine, Tsinghua University, Beijing, China.
  • Cui TT; Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China.
  • Huang LL; State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China.
  • Yan YQ; Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China.
  • Jiang ZW; Vaccine Program Office, Xiangcheng County Center for Disease Control and Prevention, Xiangcheng, HA, China.
  • Yang Q; Statistics and Decision Sicence, Beijing Key Tech Statistical Consulting Co. Ltd, Beijing, China.
  • Yu BW; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Han X; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Chen JJ; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Yang SY; R&D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.
  • Yuan L; R&D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.
  • Zhou LY; R&D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.
  • Liu G; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Li K; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Huang Z; R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China.
  • Zhao JC; R&D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China.
  • Hu ZY; State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China.
  • Xie ZQ; Division of Drug and Vaccine Research, Guangzhou Laboratory, Bioland, Guangzhou, GD, China.
Hum Vaccin Immunother ; 19(2): 2262635, 2023 08.
Article en En | MEDLINE | ID: mdl-37881130
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_pneumonia Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Adolescent / Adult / Humans / Middle aged Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_pneumonia Asunto principal: Vacunas contra la COVID-19 / COVID-19 Límite: Adolescent / Adult / Humans / Middle aged Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: China